Ascorbic acid promotes proliferation of natural killer cell populations inculture systems applicable for natural killer cell therapy

Cytotherapy

Volumn 17, Issue 5, 2015, Pages 613-620

  Huijskens, Mirelle J A J ^a   Walczak, Mateusz ^a   Sarkar, Subhashis ^a   Atrafi, Florance ^a   Senden Gijsbers, Birgit L M G ^a   Tilanus, Marcel G J ^a   Bos, Gerard M J ^a   Wieten, Lotte ^a   Germeraad, Wilfred T V ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Ascorbic acid; Cancer; Cellular immunotherapy; Hematopoietic stem cell; NK cell

Indexed keywords

ASCORBIC ACID;

ARTICLE; CELL EXPANSION; CELL HYPOXIA; CELL KILLING; CELL MATURATION; CELL THERAPY; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYMPHOCYTE COUNT; LYMPHOCYTE CULTURE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR CELL; CELL CULTURE; CELL CULTURE TECHNIQUE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; K562 CELL LINE; METABOLISM; PROCEDURES; STEM CELL; TRANSPLANTATION;

ASCORBIC ACID; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; HEMATOPOIETIC STEM CELLS; HUMANS; K562 CELLS; KILLER CELLS, NATURAL; STEM CELLS;

EID: 84933676820     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.01.004     Document Type: Article

References (31)

1. Caligiuri M.A. Human natural killer cells. Blood 2008, 112:461-469.
2. Lanier L.L. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008, 9:495-502.
3. Moretta L., Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004, 23:255-259.
4. Kang L., Voskinarian-Berse V., Law E., Reddin T., Bhatia M., Hariri A., et al. Characterization and exvivo Expansion of Human Placenta-Derived Natural Killer Cells for Cancer Immunotherapy. Front Immunol 2013, 4:101.
5. Karre K., Ljunggren H.G., Piontek G., Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986, 319:675-678.
6. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19:197-223.
7. Cheng M., Chen Y., Xiao W., Sun R., Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 2013, 10:230-252.
8. Carbone E., Neri P., Mesuraca M., Fulciniti M.T., Otsuki T., Pende D., et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005, 105:251-258.
9. Shi J., Tricot G., Szmania S., Rosen N., Garg T.K., Malaviarachchi P.A., et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008, 143:641-653.
10. Siegler U., Kalberer C.P., Nowbakht P., Sendelov S., Meyer-Monard S., Wodnar-Filipowicz A. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. Leukemia 2005, 19:2215-2222.
11. Alici E., Konstantinidis K.V., Sutlu T., Aints A., Gahrton G., Ljunggren H.G., et al. Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model. Exp Hematol 2007, 35:1839-1846.
12. Ishikawa E., Tsuboi K., Saijo K., Harada H., Takano S., Nose T., et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 2004, 24:1861-1871.
13. deMagalhaes-Silverman M., Donnenberg A., Lembersky B., Elder E., Lister J., Rybka W., et al. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. JImmunother 2000, 23:154-160.
14. Ruggeri L., Capanni M., Mancusi A., Aversa F., Martelli M.F., Velardi A. Natural killer cells as a therapeutic tool in mismatched transplantation. Best Pract Res Clin Haematol 2004, 17:427-438.
15. Velardi A., Ruggeri L., Mancusi A., Burchielli E., Perruccio K., Aversa F., et al. Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation. Semin Immunopathol 2008, 30:489-503.
16. Frings P.W., Van Elssen C.H., Wieten L., Matos C., Hupperets P.S., Schouten H.C., et al. Elimination of the chemotherapy resistant subpopulation of 4T1 mouse breast cancer by haploidentical NK cells cures the vast majority of mice. Breast Cancer Res Treat 2011, 130:773-781.
17. Krause S.W., Gastpar R., Andreesen R., Gross C., Ullrich H., Thonigs G., et al. Treatment of colon and lung cancer patients with exvivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial. Clin Cancer Res 2004, 10:3699-3707.
18. Stern M., Passweg J.R., Meyer-Monard S., Esser R., Tonn T., Soerensen J., et al. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant 2013, 48:433-438.
19. Sutlu T., Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. JIntern Med 2009, 266:154-181.
20. Luhm J., Brand J.M., Koritke P., Hoppner M., Kirchner H., Frohn C. Large-scale generation of natural killer lymphocytes for clinical application. JHematother Stem Cell Res 2002, 11:651-657.
21. McKenna D.H., Sumstad D., Bostrom N., Kadidlo D.M., Fautsch S., McNearney S., et al. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion 2007, 47:520-528.
22. Meek B., Cloosen S., Borsotti C., Van Elssen C.H., Vanderlocht J., Schnijderberg M.C., et al. Invitro-differentiated T/natural killer-cell progenitors derived from human CD34+ cells mature in the thymus. Blood 2010, 115:261-264.
23. Huijskens M.J., Walczak M., Koller N., Briedé J., Senden-Gijsbers B.L., Schnijderberg M., et al. Ascorbic acid induces development of double-positive T cells from human hematopoietic stem cells in the absence of stromal cells. JLeukoc Biol 2014, 96:1165-1175.
24. Sarkar S., Germeraad W.T., Rouschop K.M., Steeghs E.M., van Gelder M., Bos G.M., et al. Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. PloSone 2013, 8:e64835.
25. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., et al. Successful adoptive transfer and invivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
26. Ikawa T., Kawamoto H., Fujimoto S., Katsura Y. Commitment of common T/Natural killer (NK) progenitors to unipotent T and NK progenitors in the murine fetal thymus revealed by a single progenitor assay. JExp Med 1999, 190:1617-1626.
27. Cany J., van der Waart A.B., Tordoir M., Franssen G.M., Hangalapura B.N., de Vries J., et al. Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice. PloS one 2013, 8:e64384.
28. Yoon S.R., Lee Y.S., Yang S.H., Ahn K.H., Lee J.H., Kim D.Y., et al. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant 2010, 45:1038-1046.
29. Rohwer N., Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 2011, 14:191-201.
30. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47.
31. May J.M. The SLC23 family of ascorbate transporters: ensuring that you get and keep your daily dose of vitamin C. Br J Pharmacol 2011, 164:1793-1801.